MILTON, GA, March 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Attis Industries Inc. (NASDAQ: ATIS) (the "Company" or "Attis"), a diversified innovation and technology holding company, announced that it will be attending and presenting at the Biorenewable Deployment Consortium ("BDC") today in Jacksonville, FL.
The BDC is the perfect opportunity for Attis to discuss its suite of biomass conversion technologies, specific project updates and end product market development. Year after year, the BDC continues to draw some of the industry's most influential minds with regards to the valorization of biomass and its various constituents. Attis welcomes the opportunity to collaborate with industry experts and looks forward to receiving input and new perspectives from the attendees.
"We are always eager to participate in conferences like the Biorenewable Deployment Consortium," stated Jeff Cosman, Attis Industries CEO. "Conferences like the BDC are a fantastic opportunity to partake in discussions that directly impact one of Attis' core business segments. The conference format and level of competency of its attendees presents a great chance for Attis to gather alternative perspectives and network with numerous potential customers and partners."
Presenting at the conference will be Attis' VP of Marketing, Chris Kennedy. Mr. Kennedy is a 15-year veteran of the renewable fuels industry and works closely with senior management on the development of Attis' various biorefinery projects and end product market development.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "would" or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to continue to meet the listing requirements of NASDAQ; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company's go-forward business, and the risks identified and discussed under the caption "Risk Factors" in the Attis Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (the "SEC") on April 16, 2018 and the other documents Attis files with the SEC from time to time. There will be events in the future, however, that Attis is not able to predict accurately or control. Attis's actual results may differ materially from the expectations that Attis describes in its forward-looking statements. Factors or events that could cause Attis's actual results to materially differ may emerge from time to time, and it is not possible for Attis to accurately predict all of them. Any forward-looking statement made by Attis in this press release speaks only as of the date on which Attis makes it. Attis undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.